News

HDA UK Media And Political Bulletin – 25 September 2017

Media Summary

PSNC in ‘urgent’ talks with DH over ‘catastrophic’ generics shortages

Chemist and Druggist, Grace Lewis and Jennifer Offord, 22nd September 2017

 

Chemist and Druggist reports on the urgent discussions underway between The Pharmaceutical Services Negotiating Committee (PSNC) and the Department of Health (DH) about the “catastrophic” effect of generics shortages.

 

The PSNC is seeking “immediate action” from the DH following inspections by the European Medicines Agency (EMA), which found last month that a Bristol Laboratories manufacturing site in Luton, and a Dr Reddy’s site in India, did not “comply with good manufacturing practice”. This failure to comply has led to a huge supply shortage.

 

The supply shortage and pricing of a “large number of products” is having a “catastrophic impact on [contractors’] cash flow”, the PSNC said in a statement on Friday. The PSNC also said that it is “aware of the very great difficulties” and “numerous market issues that pharmacy contractors and teams are facing” and alerted the DH as soon as the extent of the issues became clear.

 

Also published in Pharmacy Biz.

 

Response to Prime Minister Theresa May’s speech in Florence

ABPI, 22nd September 2017

 

The Association of the British Pharmaceutical Industry (ABPI) responded to Theresa May’s speech on the future of the UK’s relationship with the European Union (EU) on Friday at Santa Maria Novella, Florence, Italy.

 

The ABPI’s Chief Executive Mike Thompson commented:

 

“We hope that today’s intervention delivers sufficient progress to start negotiations about issues at stake for our sector and move everyone on to thinking about how we ensure Britain has a smooth and orderly exit from the EU.

 

The Prime Minister’s speech is a welcome recognition of the importance of allowing reasonable time for industries like ours to plan and manage complicated changes in our supply chain and regulatory arrangements so that for patients across Europe, Brexit does not mean a break in their treatments.”

 

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Response to Prime Minister Theresa May’s speech in Florence

ABPI, 22nd September 2017

 

The Association of the British Pharmaceutical Industry (ABPI) have responded to today’s speech on the future of the UK’s relationship with the European Union (EU) by UK Prime Minister Theresa May at Santa Maria Novella, Florence, Italy.

 

​​​​Following the speech, The ABPI’s Chief Executive Mike Thompson commented:

 

“We hope that today’s intervention delivers sufficient progress to start negotiations about issues at stake for our sector and move everyone on to thinking about how we ensure Britain has a smooth and orderly exit from the EU.

 

The Prime Minister’s speech is a welcome recognition of the importance of allowing reasonable time for industries like ours to plan and manage complicated changes in our supply chain and regulatory arrangements so that for patients across Europe, Brexit does not mean a break in their treatments.

 

The Life Sciences sector needs not only sufficient time to reorganise our work, but also sufficient clarity about our new trading and working relationship. We need a clearly defined goal to move to in one single step in order to avoid unnecessary delay and duplication.

 

Cooperation and alignment between the UK and the EU underpins many of the achievements that our industry continues to deliver for patients across Europe. We should not let the UK’s withdrawal from the EU disrupt this work.”

HDA UK Media And Political Bulletin – 25 September 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?